Oscar Health Skyrockets 109% YTD: Time to Bet on the Stock Now?

Shares of Oscar Health OSCR have gained 108.5% year to date, outperforming the industry, its sector, as well as the Zacks S&P 500 composite in the same time frame. OSCR shares are trading at a discount to their 52-week high. 

The surge likely reflects a major profitability turnaround at Oscar Health. Strong ACA membership growth, higher revenue, improved medical-loss ratios, and better cost management significantly boosted earnings. Management’s substantial increase in 2026 profit guidance further strengthened investor confidence, leading to a major rerating of the stock.

Oscar is a leading healthcare technology company built around a full-stack technology platform. It is well-positioned for sustained growth as it strengthens its presence in the expanding U.S. individual health insurance market.

OSCR vs Industry, Sector, S&P 500 YTD

Image Source: Zacks Investment Research

Oscar’s peer, Molina Healthcare MOH, a government-focused managed-care insurer with Marketplace and Medicaid exposure, has gained 51.1% year to date, while another peer, Centene CNC, a major managed-care insurer with substantial ACA Marketplace exposure, has gained 68.5% in the same time frame.

OSCR Shares Are Expensive

The stock is overvalued compared with its industry. It is currently trading at a price-to-book multiple of 4.5, higher than the industry average of 2.67 and the median of 2.64 over five years.  It has a Value Score of B.
 

Image Source: Zacks Investment Research

 OSCR is expensive compared to Molina Healthcare and Centene.

The Case for OSCR Stock

Structural shifts in employment—including the rise of gig work, part-time jobs, self-employment and early retirement—are increasing demand for portable health insurance outside traditional employer-sponsored plans. Oscar Health is well-positioned to capitalize on this trend through its differentiated technology platform, which integrates plan design, member engagement, care navigation, claims processing and provider management. Its Individual Coverage Health Reimbursement Arrangements, Lucie Health marketplace and Trove Group also create growth opportunities beyond the core insurance business.

Strong membership growth reflects rising acceptance of Oscar’s offerings. Membership reached 2.96 million as of June 30, 2026, up 46% year over year. Second-quarter revenues jumped 70% to $4.88 billion, supported by membership gains and premium-rate increases. Oscar expects 2026 revenues of $18.7-$19.0 billion, demonstrating its growing scale in the individual insurance market.

The company plans to enter more than 150 additional metropolitan statistical areas by 2027. Disciplined pricing, consumer-focused products and a scalable technology platform should support continued expansion in the Affordable Care Act marketplace. Oscar’s strategy also aligns with major healthcare trends, including rising costs, consumerization, digitization and greater personalization. Its early focus on these areas could provide a sustainable competitive advantage as the healthcare system evolves.

Management targets a 20% revenue CAGR through 2027 and a 5% operating margin next year. Technology and AI initiatives, fixed-cost leverage and lower risk-adjustment expenses as a percentage of premiums are already helping improve the expense ratio.

Oscar’s financial position has also strengthened. As of June 30, 2026, it held approximately $4.08 billion in cash and cash equivalents and $6.08 billion in investments, compared with long-term debt of roughly $432 million. This liquidity provides ample flexibility to meet regulatory capital requirements, fund technology investments and support continued membership growth.

Optimistic Analyst Sentiment

The Zacks Consensus Estimate for 2026 and 2027 revenues indicates a 60.8% and 9.6% year-over-year increase, respectively. The same for 2026 and 2027 earnings implies a 191.2% and 15.8% year-over-year increase, respectively.  

The expected earnings growth rate is pegged at 31.5%, better than the industry average of 12.8%. The company has a Growth Score of A.

The consensus estimate for 2026 and 2027 earnings has moved 144.4% and 31.6% north, respectively, in the past 30 days. 

Image Source: Zacks Investment Research

The consensus estimates for 2026 and 2027 earnings of Molina Healthcare, as well as Centene, witnessed upward movement in the past 30 days.

How to Play OSCR Shares

Oscar’s expanding membership, improving cost structure, scalable technology platform, consistent underwriting discipline and solid balance sheet will help it convert its strong results into durable earnings. Its VGM Score of A instills confidence.  

Optimistic analyst sentiment, price appreciation and discounted valuation make this Zacks Rank #2 (Buy) stock a strong contender for addition to one’s portfolio. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
 

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research